Issue 37, 2018, Issue in Progress

Chiral ruthenium(ii) complex as potent radiosensitizer of 125I through DNA-damage-mediated apoptosis

Abstract

A chiral ruthenium(II) complex, Λ-[Ru(bpy)2(o-tFMPIP)] (ClO4)2 (o-tFMPIP = 2′-trifluoromethylphenyl) imidazo [4,5-f][1,10]phenanthroline, was prepared and evaluated for its enhancement of the radiosensitivity of 125I seeds. The synthetic Ru(II) complex, LR042, effectively enhanced growth inhibition against HepG2 human hepatocellular liver carcinoma cells induced by 125I seeds and consequently effectively promoted the apoptosis of tumor cells with increasing level of cleave-caspase-3. Furthermore, the results of immunofluorescence indicated that LR042 enhanced the phosphorylation of H2AX by 125I seeds vigorously in response to damaged DNA. LR042 improved DNA damage induced by 125I seeds, which resulted in apoptosis through the activation of the p53/AKT signal. In conclusion, synthetic LR042 can be further developed as a potential radiosensitizer of 125I seed radiotherapy for cancer therapy.

Graphical abstract: Chiral ruthenium(ii) complex as potent radiosensitizer of 125I through DNA-damage-mediated apoptosis

Supplementary files

Article information

Article type
Paper
Submitted
19 Apr 2018
Accepted
15 May 2018
First published
06 Jun 2018
This article is Open Access
Creative Commons BY license

RSC Adv., 2018,8, 20612-20618

Chiral ruthenium(II) complex as potent radiosensitizer of 125I through DNA-damage-mediated apoptosis

M. Bai, Z. Zeng, L. Li, Q. Wu, Y. Zhang, T. Pan, L. Mu, D. Zhu, S. Guan, Q. Xie and W. Mei, RSC Adv., 2018, 8, 20612 DOI: 10.1039/C8RA03383H

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements